<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02195869</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-1129-CA</org_study_id>
    <nct_id>NCT02195869</nct_id>
  </id_info>
  <brief_title>Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease</brief_title>
  <official_title>A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacyclics LLC.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and clinical efficacy of ibrutinib in
      subjects with steroid dependent or refractory Chronic Graft Versus Host Disease.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b: Number of dose-limiting toxicities as a measure of safety profile to determine recommended dose of ibrutinib</measure>
    <time_frame>28 treatment days after last subject enrolled in Phase 1 dose level(s).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 (Efficacy): Overall cGVHD response rate defined as the proportion of evaluable subjects who achieve a [NIH-defined Complete Response (CR) and Partial Response (PR)] over all subjects who were treated with RP2D</measure>
    <time_frame>When the last subject completes 6 months of treatment.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Failure Free Survival (FFS)</measure>
    <time_frame>When the last subject completes 6 and 12 months of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in symptom burden by the Lee cGVHD Symptom Scale</measure>
    <time_frame>Approximately 18 months after last subject is enrolled or up to disease progression, whichever occurs first.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corticosteroid requirement changes over Time</measure>
    <time_frame>Approximately 18 months after last subject is enrolled or up to disease progression, whichever occurs first.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Adverse Events (AE) as a measure of safety and tolerability of ibrutinib</measure>
    <time_frame>Approximately 18 months after last subject is enrolled.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the plasma pharmacokinetics of ibrutinib and the metabolite, PCI-45227</measure>
    <time_frame>Samples will be collected during the first two weeks of subject receiving study drug and will be assessed approximately 1 month after completion of the PK sample collections of the last subject enrolled at each dose level.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>Phase 1b: Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib PO administered daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib (PO) administered daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib (PO) administered daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib (PO) administered daily for 18 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <arm_group_label>Phase 1b: Dose Level 1</arm_group_label>
    <arm_group_label>Phase 1b: Dose Level 2</arm_group_label>
    <arm_group_label>Phase 1b: Dose Level 3</arm_group_label>
    <arm_group_label>Phase 2</arm_group_label>
    <other_name>PCI32765</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Steroid dependent or refractory classic chronic GVHD disease.

          -  No more than 3 previous treatments for cGVHD.

          -  Receiving baseline systemic glucocorticoid therapy (at stable dose) for cGVHD at study
             entry.

          -  Men and women ≥18 years old.

          -  Karnofsky performance status ≥60.

        Exclusion Criteria:

          -  Known or suspected active acute GVHD.

          -  Current treatment with sirolimus AND either cyclosporine or tacrolimus.

          -  History of treatment with a tyrosine kinase inhibitor (eg, imatinib), purine analogs
             or other cancer chemotherapy in the 4 weeks prior to starting study drug.

          -  Currently active, clinically significant cardiovascular disease.

          -  Uncontrolled infections not responsive to antibiotics, antiviral medicines, or
             antifungal medicines or a recent infection requiring systemic treatment that was
             completed ≤14 days before the first dose of study drug.

          -  Progressive underlying malignant disease including post-transplant lymphoproliferative
             disease.

          -  History of other malignancy (not including the underlying malignancy that was the
             indication for transplant)

          -  Concomitant use of warfarin or other Vitamin K antagonists

          -  Known bleeding disorders or hemophilia.

          -  History of stroke or intracranial hemorrhage within 6 months prior to enrollment.

          -  Known history of human immunodeficiency virus (HIV) or active with hepatitis C virus
             (HCV) or hepatitis B virus (HBV).

          -  Concurrent use of a strong cytochrome P450(CYP) 3A inhibitor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lori Styles, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pharmacyclics LLC.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University, Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center, Henry-Joyce Cancer Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2014</study_first_submitted>
  <study_first_submitted_qc>July 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2014</study_first_posted>
  <last_update_submitted>April 13, 2016</last_update_submitted>
  <last_update_submitted_qc>April 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCYC1129</keyword>
  <keyword>PCYC1129CA</keyword>
  <keyword>1129</keyword>
  <keyword>Ibrutinib</keyword>
  <keyword>PCI32765</keyword>
  <keyword>IMBRUVICA</keyword>
  <keyword>Pharmacyclics</keyword>
  <keyword>PCYC</keyword>
  <keyword>GVHD</keyword>
  <keyword>Steroid dependent</keyword>
  <keyword>refractory</keyword>
  <keyword>chronic</keyword>
  <keyword>graft versus host disease</keyword>
  <keyword>chronic graft versus host disease</keyword>
  <keyword>immunology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

